1. Home
  2. BUR vs NVCR Comparison

BUR vs NVCR Comparison

Compare BUR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burford Capital Limited

BUR

Burford Capital Limited

HOLD

Current Price

$4.99

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$12.94

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUR
NVCR
Founded
2009
2000
Country
Guernsey
Switzerland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
BUR
NVCR
Price
$4.99
$12.94
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$13.58
$28.08
AVG Volume (30 Days)
6.1M
1.0M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
2.68%
N/A
EPS Growth
N/A
21.79
EPS
0.28
N/A
Revenue
$413,360,000.00
$655,353,000.00
Revenue This Year
$104.62
$7.72
Revenue Next Year
N/A
$6.74
P/E Ratio
$16.70
N/A
Revenue Growth
N/A
8.28
52 Week Low
$3.59
$9.82
52 Week High
$14.61
$20.05

Technical Indicators

Market Signals
Indicator
BUR
NVCR
Relative Strength Index (RSI) 37.83 63.26
Support Level $3.59 $12.66
Resistance Level $9.59 $13.34
Average True Range (ATR) 0.30 0.54
MACD 0.13 0.28
Stochastic Oscillator 97.31 92.75

Price Performance

Historical Comparison
BUR
NVCR

About BUR Burford Capital Limited

Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: